News
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
How Eli Lilly's GLP-1 pill could transform the weight-loss space
Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill trial. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination with Host Josh Lipton,
We recently published a list of the 10 Innovative Healthcare Stocks to Watch in 2025. In this article, we are going to take a ...
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
Eli Lilly (NYSE:LLY) experienced a 2% decline last week, a movement that contrasts with a broader market drop of 3%. The ...
9hon MSN
We recently published a list of 15 Best Blue Chip Stocks to Buy According to Billionaires. In this article, we are going to ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...
Blue-chip stocks are known for their stability and long-term growth potential, making them a favorite among investors. Our recent analysis identified 15 top blue-chip stocks, including Eli Lilly, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback